Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration

Shri N. Giri, Qingjian Wang, Yan Xie, Jozsef Lango, Dexter Morin, Solomon B. Margolin, Alan R Buckpitt

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The present study describes the pharmacokinetics and metabolism of pirfenidone (PD), a compound which has been shown to have significant antifibrotic effects in rodent models of pulmonary and cardiac fibrosis. Despite the fact that this compound is currently in phase II clinical trials, little data are available on the metabolism and disposition of this agent in rodents or humans. Radioactive PD [benzene ring 14C(U)] was administered i.v. to mice at 40 mg PD/kg body weight, and animals were killed at varying times for determination of parent compound and metabolites in various tissues. The disappearance of parent compound from the plasma followed apparent 2-compartment elimination kinetics with a terminal elimination half-life of 8.6 min. Cl (0.10 ml/min/g) and Vd(ss) (0.67 ml/g) indicated that PD was rapidly distributed in body water. This is consistent with the finding that peak tissue radioactivity occurred within 5 min following the i.v. administration of [14C]-PD and that well-perfused tissues, kidney>liver>lung have much higher levels of parent compound and metabolites than did fat. Two peaks isolated from plasma samples by HPLC yielded mass spectra that were consistent with initial oxidation to the alcohol followed by further metabolism to the carboxylic acid. The radioactivity recovered in the 24 h urine samples averaged 97% of the administered dose and none of that was associated with the parent compound. The short plasma half-life of parent compound in mice supports the need for additional studies in humans where the compound has been shown to have clinical benefits.

Original languageEnglish (US)
Pages (from-to)203-211
Number of pages9
JournalBiopharmaceutics and Drug Disposition
Volume23
Issue number5
DOIs
StatePublished - Jul 2002

Fingerprint

Intravenous Administration
Pharmacokinetics
Pharmaceutical Preparations
Radioactivity
Half-Life
Rodentia
Phase II Clinical Trials
Body Water
Pulmonary Fibrosis
Carboxylic Acids
Benzene
Fats
High Pressure Liquid Chromatography
Body Weight
Alcohols
pirfenidone
Urine
Kidney
Lung
Liver

Keywords

  • Antifibrotic drug
  • Metabolism
  • Pharmacokinetics
  • Pirfenidone

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. / Giri, Shri N.; Wang, Qingjian; Xie, Yan; Lango, Jozsef; Morin, Dexter; Margolin, Solomon B.; Buckpitt, Alan R.

In: Biopharmaceutics and Drug Disposition, Vol. 23, No. 5, 07.2002, p. 203-211.

Research output: Contribution to journalArticle

Giri, Shri N. ; Wang, Qingjian ; Xie, Yan ; Lango, Jozsef ; Morin, Dexter ; Margolin, Solomon B. ; Buckpitt, Alan R. / Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. In: Biopharmaceutics and Drug Disposition. 2002 ; Vol. 23, No. 5. pp. 203-211.
@article{150d74a48b7c4eb7955329c5007c3ea0,
title = "Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration",
abstract = "The present study describes the pharmacokinetics and metabolism of pirfenidone (PD), a compound which has been shown to have significant antifibrotic effects in rodent models of pulmonary and cardiac fibrosis. Despite the fact that this compound is currently in phase II clinical trials, little data are available on the metabolism and disposition of this agent in rodents or humans. Radioactive PD [benzene ring 14C(U)] was administered i.v. to mice at 40 mg PD/kg body weight, and animals were killed at varying times for determination of parent compound and metabolites in various tissues. The disappearance of parent compound from the plasma followed apparent 2-compartment elimination kinetics with a terminal elimination half-life of 8.6 min. Cl (0.10 ml/min/g) and Vd(ss) (0.67 ml/g) indicated that PD was rapidly distributed in body water. This is consistent with the finding that peak tissue radioactivity occurred within 5 min following the i.v. administration of [14C]-PD and that well-perfused tissues, kidney>liver>lung have much higher levels of parent compound and metabolites than did fat. Two peaks isolated from plasma samples by HPLC yielded mass spectra that were consistent with initial oxidation to the alcohol followed by further metabolism to the carboxylic acid. The radioactivity recovered in the 24 h urine samples averaged 97{\%} of the administered dose and none of that was associated with the parent compound. The short plasma half-life of parent compound in mice supports the need for additional studies in humans where the compound has been shown to have clinical benefits.",
keywords = "Antifibrotic drug, Metabolism, Pharmacokinetics, Pirfenidone",
author = "Giri, {Shri N.} and Qingjian Wang and Yan Xie and Jozsef Lango and Dexter Morin and Margolin, {Solomon B.} and Buckpitt, {Alan R}",
year = "2002",
month = "7",
doi = "10.1002/bdd.311",
language = "English (US)",
volume = "23",
pages = "203--211",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration

AU - Giri, Shri N.

AU - Wang, Qingjian

AU - Xie, Yan

AU - Lango, Jozsef

AU - Morin, Dexter

AU - Margolin, Solomon B.

AU - Buckpitt, Alan R

PY - 2002/7

Y1 - 2002/7

N2 - The present study describes the pharmacokinetics and metabolism of pirfenidone (PD), a compound which has been shown to have significant antifibrotic effects in rodent models of pulmonary and cardiac fibrosis. Despite the fact that this compound is currently in phase II clinical trials, little data are available on the metabolism and disposition of this agent in rodents or humans. Radioactive PD [benzene ring 14C(U)] was administered i.v. to mice at 40 mg PD/kg body weight, and animals were killed at varying times for determination of parent compound and metabolites in various tissues. The disappearance of parent compound from the plasma followed apparent 2-compartment elimination kinetics with a terminal elimination half-life of 8.6 min. Cl (0.10 ml/min/g) and Vd(ss) (0.67 ml/g) indicated that PD was rapidly distributed in body water. This is consistent with the finding that peak tissue radioactivity occurred within 5 min following the i.v. administration of [14C]-PD and that well-perfused tissues, kidney>liver>lung have much higher levels of parent compound and metabolites than did fat. Two peaks isolated from plasma samples by HPLC yielded mass spectra that were consistent with initial oxidation to the alcohol followed by further metabolism to the carboxylic acid. The radioactivity recovered in the 24 h urine samples averaged 97% of the administered dose and none of that was associated with the parent compound. The short plasma half-life of parent compound in mice supports the need for additional studies in humans where the compound has been shown to have clinical benefits.

AB - The present study describes the pharmacokinetics and metabolism of pirfenidone (PD), a compound which has been shown to have significant antifibrotic effects in rodent models of pulmonary and cardiac fibrosis. Despite the fact that this compound is currently in phase II clinical trials, little data are available on the metabolism and disposition of this agent in rodents or humans. Radioactive PD [benzene ring 14C(U)] was administered i.v. to mice at 40 mg PD/kg body weight, and animals were killed at varying times for determination of parent compound and metabolites in various tissues. The disappearance of parent compound from the plasma followed apparent 2-compartment elimination kinetics with a terminal elimination half-life of 8.6 min. Cl (0.10 ml/min/g) and Vd(ss) (0.67 ml/g) indicated that PD was rapidly distributed in body water. This is consistent with the finding that peak tissue radioactivity occurred within 5 min following the i.v. administration of [14C]-PD and that well-perfused tissues, kidney>liver>lung have much higher levels of parent compound and metabolites than did fat. Two peaks isolated from plasma samples by HPLC yielded mass spectra that were consistent with initial oxidation to the alcohol followed by further metabolism to the carboxylic acid. The radioactivity recovered in the 24 h urine samples averaged 97% of the administered dose and none of that was associated with the parent compound. The short plasma half-life of parent compound in mice supports the need for additional studies in humans where the compound has been shown to have clinical benefits.

KW - Antifibrotic drug

KW - Metabolism

KW - Pharmacokinetics

KW - Pirfenidone

UR - http://www.scopus.com/inward/record.url?scp=0036647071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036647071&partnerID=8YFLogxK

U2 - 10.1002/bdd.311

DO - 10.1002/bdd.311

M3 - Article

C2 - 12116052

AN - SCOPUS:0036647071

VL - 23

SP - 203

EP - 211

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 5

ER -